AN OPEN‐LABEL TRIAL OF ORAL CA‐4948 AN IRAK4 INHIBITOR COMBINED WITH IBRUTINIB IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

Authors :: Lori A. Leslie
Allison C. Rosenthal
Han W. Tun
Radhakrishnan Ramchandren
R. von Roemeling
G.S. Nowakowski
Erel Joffe
Monica Mead
Elizabeth Ferreira Martinez
M. Lunning
Source :: Hematological Oncology. 39
Publication Year :: 2021
Publisher :: Wiley, 2021.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Adult patients
business.industry
Hematology
General Medicine
chemistry.chemical_compound
Refractory
chemistry
Internal medicine
Ibrutinib
medicine
Open label
business

Full Text Access

Tools